Research programme: antifungals - F2G

Drug Profile

Research programme: antifungals - F2G

Alternative Names: F3; F3 series; FG-3409

Latest Information Update: 07 Sep 2012

Price : $50

At a glance

  • Originator F2G
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Aspergillosis; Mycoses

Most Recent Events

  • 05 Sep 2012 Preclinical development is ongoing in the UK
  • 25 Oct 2008 Preclinical trials in Aspergillosis in United Kingdom (IV)
  • 25 Oct 2008 Preclinical trials in Aspergillosis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top